Dimerix has strengthened its kidney disease pipeline with a US patent grant for DMX-652, extending protection until 2043 and setting the stage for a Phase 2 trial targeting acute kidney injury after cardiac surgery.
- US patent granted for DMX-652 extending protection to 2043
- Phase 2 clinical trial preparations underway for acute kidney injury
- DMX-652 targets mitochondrial enzyme USP30 to prevent kidney damage
- No approved therapies currently exist for acute kidney injury
- Dimerix’s broader pipeline includes Phase 3 asset DMX-200 for FSGS
US Patent Boosts DMX-652’s Commercial Appeal
Dimerix Limited (ASX:DXB) has secured a pivotal US patent for DMX-652, its newly acquired Phase 2-ready drug candidate aimed at acute kidney injury (AKI). The patent, covering the compound’s composition of matter, extends protection until April 2043; two years longer than originally anticipated following a patent term adjustment by the US Patent and Trademark Office. This extension notably enhances the commercial attractiveness of DMX-652 in a market starved of effective treatments.
Targeting a Critical Unmet Need in Acute Kidney Injury
DMX-652 is designed as a first-in-class inhibitor of USP30, a mitochondrial enzyme implicated in the clearance of damaged mitochondria. By supporting mitochondrial quality control, the drug aims to prevent kidney injury and promote recovery of kidney function. The initial focus is on AKI associated with cardiac surgery, where roughly 25% of patients suffer rapid kidney decline post-operation. With no approved therapies currently available, DMX-652 could address a substantial clinical burden affecting an estimated 260,000 patients annually across major Western markets.
Phase 2 Trial Readiness and Regulatory Backing
Dimerix is preparing to initiate a Phase 2 clinical trial under an existing US Investigational New Drug (IND) application that has FDA approval. The trial will investigate DMX-652’s potential to prevent kidney injury and preserve renal function in patients undergoing cardiac surgery. The acquisition of DMX-652 included not only the patent rights but also pharmaceutical-grade drug supply and manufacturing protocols, positioning Dimerix to advance clinical development swiftly.
Expanding Dimerix’s Kidney Disease Pipeline
This patent grant and clinical trial preparation mark a significant expansion of Dimerix’s renal disease portfolio, complementing its lead asset DMX-200, currently in Phase 3 for focal segmental glomerulosclerosis (FSGS). While DMX-200 targets a rare kidney disorder with an inflammatory component, DMX-652 addresses a common acute condition with high morbidity and mortality. Together, these programs underscore Dimerix’s strategic focus on kidney diseases with high unmet medical need.
Commercial and Clinical Implications
The patent protection until 2043 offers a lengthy runway for DMX-652’s development and potential market exclusivity in the US. Given the lack of current therapies for AKI and the serious outcomes associated with the condition; including prolonged intensive care, dialysis dependency, and increased mortality; the drug could fill a critical gap in treatment. However, clinical success remains to be demonstrated in the upcoming Phase 2 trial, and the broader commercial opportunity will depend on trial outcomes and regulatory pathways.
Bottom Line?
The extended US patent for DMX-652 solidifies Dimerix’s foothold in kidney disease therapeutics as it gears up for a crucial Phase 2 trial in acute kidney injury.
Questions in the middle?
- How will DMX-652’s Phase 2 trial results shape its commercial trajectory in AKI?
- What are the prospects for expanding DMX-652’s indications beyond cardiac surgery-associated AKI?
- How might Dimerix leverage its patent portfolio to fend off competition in the kidney disease market?